巴西研究:科兴疫苗对变异新冠病毒有效率50% -6park.com
留园网,海外华人论坛,海外华人第一网站,巴西研究:科兴疫苗对变异新冠病毒有效率50% -6park.com
www.6parknews.com
智利科兴疫苗的结果出来了
- 主题发起人 eetimes
- 开始时间
billwanhua
本站元老
- 注册
- 2005-07-07
- 消息
- 16,262
- 荣誉分数
- 5,275
- 声望点数
- 373
CoronaVac first dose is effective against Manaus Covid-19 variant - preliminary study
Preliminary results of a research conducted by the Vebra Covid-19 group released on Wednesday, 7, pointed out that CoronaVac - the most used vaccine in Brazil today - is 50% effective against symptomatic cases of infection by the P.1 variant, the one from Manaus, also called Brazilian variant.
riotimesonline.com
这就有意思了，两个国家结果十万八千里。等等看吧。
The study involved 67,718 health workers in the capital of the state of Amazonas, where the P.1 mutation is prevalent
样本数据不少，67,718 health workers
Coronavac tem 50% de efetividade contra variante P.1, mostra estudo em Manaus | CNN Brasil
Estudo com 67 mil profissionais de saúde da capital do Amazonas mostra que imunizante preveniu doença sintomática pela Covid-19
www.cnnbrasil.com.br
A study involving 67,718 health workers in the city of Manaus showed that Coronavac , a vaccine against Covid-19 produced by the Butantan Institute, is 50% effective in preventing illness from Covid-19 14 days after the first dose.
The interim effectiveness analysis carried out by the Vebra Covid-19 group is the first to assess the effectiveness of Coronavac in places where the P.1 variant , known as the Manaus variant, is predominant.
"The data are preliminary, we only had enough events to evaluate 14 days after the first dose and, even so, it proved to be effective and with that value of 50%", Julio Croda, an infectologist at the Oswaldo Cruz Foundation (Fiocruz) , told CNN and study coordinator.
According to Vebra Covid-19, which involves researchers from national and international institutions, in addition to servers in the health departments of the states of Amazonas and São Paulo and the health departments of the cities of Manaus and São Paulo, data related to effectiveness 14 days after the second dose of the vaccine will be collected over the next few weeks.
"[Coronavac] protects against symptomatic diseases. And this is very good, it shows that in practice the vaccine continues to work for the variant and that Brazil can continue to use this vaccine in the states where it is dominant", added Croda.
The researcher also pointed out that the researchers will also evaluate the effectiveness of Coronavac and the Astrazeneca / Oxford vaccine in the elderly in the city of Manaus, Campo Grande, São Paulo and in the state of São Paulo.
In a note released on Wednesday, the researchers at Vebra Covid-19 considered the results encouraging because they showed that Coronavac “continues to be effective in reducing the risk of symptomatic disease in a scenario with a prevalence of P.1 greater than 50%”.
"These findings support the continued use of this vaccine in Brazil and in other countries with the circulation of the same variant," said the group.
等等看吧，巴西说马上要公布英国疫苗效果。巴西公布的中国疫苗效果比较好。
最后编辑:
- 注册
- 2005-11-23
- 消息
- 30,321
- 荣誉分数
- 7,459
- 声望点数
- 373
国产四种疫苗有效率从50%到79%
来源: heisse 于 2021-04-06 21:47:05
Each of the following vaccines has received use authorization in at least one country.
| Name | Manufacturer | Type of vaccine | Efficacy rate |
|---|---|---|---|
| BNT162b2 | Pfizer-BioNTech | mRNA | 95% |
| mRNA-1273 | Moderna | mRNA | 94.5% |
| Ad26.COV2.S | Janssen (Johnson & Johnson) | Viral vector | 66% |
| AZD1222 | Oxford-AstraZeneca | Viral vector | 81.3%Trusted Source |
| Covishield* | Serum Institute of India | Viral vector | 81.3% |
| Ad5-nCov | CanSino | Viral vector | 65.28% |
| Sputnik V | Gamaleya | Viral vector | 91.6%Trusted Source |
| Covaxin | Bharat Biotech | Inactivated | 80.6% |
| BBIBP-CorV | Sinopharm (Beijing) | Inactivated | 79.34%Trusted Source |
| Inactivated (Vero Cell) | Sinopharm (Wuhan) | Inactivated | 72.51% |
| CoronaVac | Sinovac | Inactivated | 50.38% |
| RBD-dimer | Anhui Zhifei Longcom | Protein subunit | Unknown |
| EpiVacCorona | FBRI | Protein subunit | Unknown |
* Covishield is the Oxford-AstraZeneca vaccine produced for India.
国产四种疫苗有效率从50%到79% - heisse发表于 健康养生 - 论坛 | 文学城
bbs.wenxuecity.com
- 注册
- 2012-09-04
- 消息
- 64,310
- 荣誉分数
- 11,629
- 声望点数
- 1,373
- 注册
- 2012-09-04
- 消息
- 64,310
- 荣誉分数
- 11,629
- 声望点数
- 1,373
来源在这里CoronaVac first dose is effective against Manaus Covid-19 variant - preliminary study
Preliminary results of a research conducted by the Vebra Covid-19 group released on Wednesday, 7, pointed out that CoronaVac - the most used vaccine in Brazil today - is 50% effective against symptomatic cases of infection by the P.1 variant, the one from Manaus, also called Brazilian variant.
这就有意思了，两个国家结果十万八千里。等等看吧。
The study involved 67,718 health workers in the capital of the state of Amazonas, where the P.1 mutation is prevalent
样本数据不少，67,718 health workers
这个是巴西cnn 报道。Coronavac tem 50% de efetividade contra variante P.1, mostra estudo em Manaus | CNN Brasil
Estudo com 67 mil profissionais de saúde da capital do Amazonas mostra que imunizante preveniu doença sintomática pela Covid-19
A study involving 67,718 health workers in the city of Manaus showed that Coronavac , a vaccine against Covid-19 produced by the Butantan Institute, is 50% effective in preventing illness from Covid-19 14 days after the first dose.
The interim effectiveness analysis carried out by the Vebra Covid-19 group is the first to assess the effectiveness of Coronavac in places where the P.1 variant , known as the Manaus variant, is predominant.
"The data are preliminary, we only had enough events to evaluate 14 days after the first dose and, even so, it proved to be effective and with that value of 50%", Julio Croda, an infectologist at the Oswaldo Cruz Foundation (Fiocruz) , told CNN and study coordinator.
According to Vebra Covid-19, which involves researchers from national and international institutions, in addition to servers in the health departments of the states of Amazonas and São Paulo and the health departments of the cities of Manaus and São Paulo, data related to effectiveness 14 days after the second dose of the vaccine will be collected over the next few weeks.
"[Coronavac] protects against symptomatic diseases. And this is very good, it shows that in practice the vaccine continues to work for the variant and that Brazil can continue to use this vaccine in the states where it is dominant", added Croda.
The researcher also pointed out that the researchers will also evaluate the effectiveness of Coronavac and the Astrazeneca / Oxford vaccine in the elderly in the city of Manaus, Campo Grande, São Paulo and in the state of São Paulo.
In a note released on Wednesday, the researchers at Vebra Covid-19 considered the results encouraging because they showed that Coronavac “continues to be effective in reducing the risk of symptomatic disease in a scenario with a prevalence of P.1 greater than 50%”.
"These findings support the continued use of this vaccine in Brazil and in other countries with the circulation of the same variant," said the group.
等等看吧，巴西说马上要公布英国疫苗效果。巴西公布的中国疫苗效果比较好。
第一针，对巴西有效，对智利无效。
我好奇美国的疫苗在巴西是啥效果？
billwanhua
本站元老
- 注册
- 2005-07-07
- 消息
- 16,262
- 荣誉分数
- 5,275
- 声望点数
- 373
这个不一定矛盾，巴西说：
is 50% effective in preventing illness
results encouraging because they showed that Coronavac “continues to be effective in reducing the risk of symptomatic disease in a scenario with a prevalence of P.1 greater than 50%”.
这个可能依然感染，但是对症状有防护作用。如果要是对感染的防护是50%， 那就赶上pfizer的 疫苗了，而且是变异病毒。
不过这种新闻报道，不是正式发表的文章，只能 take with a grain of salt.
最后编辑:
相关推荐
